



Press Release

Hamburg / Princeton, June 7th 2010

Transient Bulk Transfection by Flow Electroporation CCS Launches New Custom Service

CCS Cell Culture Service has established a new technology which is now offered as a custom service to clients within drug discovery industries. By using the MaxCyte[®] STX[™] Scalable Transfection System CCS is able to transfect batches of up to 10 billion cells in less than 30 minutes. Cell lines, primary cells and stem cells are reproducibly and efficiently transfected while maintaining the integrity of the cells for subsequent assays. As a result, bulk quantities of assay-ready frozen instant cells which are transiently expressing targets of interest can now be rapidly prepared.

"We are very excited about this technology. Difficult targets or target complexes can now be easily addressed in a high-throughput screening scale by using large quantities of validated transiently transfected cells, even in more in vivo-like cellular backgrounds." comments Dr. Oliver Klotzsche, Managing Director of CCS.

"We are very pleased that CCS has decided to acquire the MaxCyte STX. By providing transient bulk transfection as a custom service, CCS enables everybody to benefit from our technology and helps to get it established as an important tool for drug discovery." states Douglas Doerfler, President and CEO at MaxCyte.

About CCS Cell Culture Service

CCS is dedicated to improving the output of drug discovery research by providing custom made cell based reagents. For more than ten years, CCS has been supporting the research departments of pharmaceutical and biotechnology companies in their efforts to discover new drug entities. Originally established as a general provider of research services, CCS has advanced to become a custom supplier of recombinant cell lines, assay-ready frozen cells, qualified membranes and proteins for high-throughput-screening. Major pharmaceutical companies all over Europe and the USA now rely on the custom products and services of CCS. (<http://www.cellcultureservice.com>)

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed the MaxCyte[®] STX[™] Scalable Transfection System for the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for cell-based screening assays for ion channels, GPCRs, and other targets, with comparable results and Seamless Scalability[™] from the bench to HTS scale. (<http://www.maxcyte.com/cell-based-screening.shtml>)

Contact:

CCS Cell Culture Service – USA & Canada

Richard Field
COO, North America
Phone: (732) 329 2355
Email: Field@CellCultureService.com

MaxCyte

Karen A. Donato, Ph.D.
Executive Vice President Sales and Marketing
Phone: (301) 944-1700
Email: kdonato@maxcyte.com

CCS Cell Culture Service – Europe

Susan Friedemann
Sales & Communication
Phone: +49 (40) 471 965 75
Email: Friedemann@CellCultureService.com